CRBP · Insider Trading
Corbus Pharmaceuticals Holdings, Inc.
Every open-market purchase and sale reported by CRBP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-02 | Cormorant Global Healthcare Master Fund, LP | — | Sell | −425,000 | −$1.74M |
| 2026-09-15 | Yong Ben | Director | Sell | −2,000 | −$15.68K |
| 2026-08-17 | Leonardo Viana Nicacio | Chief Medical Officer | A | +58,333 | — |
| 2026-08-12 | Nishant C Saxena | Chief Business Officer | Buy | +2,600 | +$25.04K |
| 2026-08-10 | Sean F. Moran | Chief Financial Officer | Sell | −12,000 | −$120.97K |
| 2026-08-10 | Yuval Cohen | Chief Executive Officer | Sell | −17,000 | −$171.40K |
| 2026-06-11 | Anne Altmeyer | Director | Sell | −2,412 | −$19.09K |
| 2026-06-11 | Winston Kung | Director | Sell | −2,026 | −$16.03K |
| 2026-06-11 | John Kenneth Jenkins | Director | Sell | −4,800 | −$37.99K |
| 2026-06-03 | Nishant C Saxena | Chief Business Officer | Buy | +13,500 | +$101.22K |
| 2026-05-22 | Nishant C Saxena | Chief Business Officer | A | +58,300 | — |
| 2026-05-21 | John Kenneth Jenkins | Director | A | +3,800 | — |
| 2026-05-21 | Rachelle Suzanne Jacques | Director | A | +3,800 | — |
| 2026-05-21 | Brent Pfeiffenberger | Director | A | +7,500 | — |
| 2026-05-21 | Yong Ben | Director | A | +3,800 | — |
| 2026-05-21 | Anne Altmeyer | Director | A | +3,800 | — |
| 2026-05-21 | Winston Kung | Director | A | +3,800 | — |
| 2026-03-04 | Dominic Smethurst | Chief Medical Officer | Sell | −6,097 | −$50.60K |
| 2026-02-18 | Sean F. Moran | Chief Financial Officer | Sell | −4,701 | −$36.59K |
| 2026-02-18 | Yuval Cohen | Chief Executive Officer | Sell | −13,871 | −$107.95K |
| 2026-02-18 | Ian Hodgson | Chief Operating Officer | Sell | −847 | −$6.25K |
| 2026-02-04 | Ian Hodgson | Chief Operating Officer | Sell | −2,415 | −$19.54K |
| 2026-02-04 | Dominic Smethurst | Chief Medical Officer | Sell | −3,285 | −$26.57K |
| 2026-01-16 | Yuval Cohen | Chief Executive Officer | A | +50,000 | — |
| 2026-01-16 | Ian Hodgson | Chief Operating Officer | A | +28,365 | — |
| 2026-01-16 | Sean F. Moran | Chief Financial Officer | A | +28,082 | — |
| 2026-01-16 | Dominic Smethurst | Chief Medical Officer | A | +28,365 | — |
| 2025-12-15 | Cormorant Asset Management, LP | 10%+ Owner | Sell | −30,029 | −$344.01K |
| 2025-10-27 | Sean F. Moran | Chief Financial Officer | MIXED | — | −$165.64K |
| 2025-10-27 | Yuval Cohen | Chief Executive Officer | MIXED | — | −$353.49K |
| 2025-10-21 | Anne Altmeyer | Director | MIXED | — | −$16.64K |
| 2025-06-02 | Alan F Holmer | Director | A | +4,800 | — |
| 2025-06-02 | Winston Kung | Director | A | +4,800 | — |
| 2025-06-02 | Rachelle Suzanne Jacques | Director | A | +4,800 | — |
| 2025-06-02 | Anne Altmeyer | Director | MIXED | +3,408 | −$10.10K |
| 2025-06-02 | John Kenneth Jenkins | Director | MIXED | +2,017 | −$20.47K |
| 2025-06-02 | Yong Ben | Director | A | +4,800 | — |
| 2025-03-07 | Dominic Smethurst | Chief Medical Officer | Sell | −6,393 | −$43.33K |
| 2025-02-18 | Sean F. Moran | Chief Financial Officer | Sell | −2,792 | −$24.45K |
| 2025-02-18 | Yuval Cohen | Chief Executive Officer | Sell | −7,134 | −$62.46K |
| 2025-02-04 | Yuval Cohen | Chief Executive Officer | A | +68,100 | — |
| 2025-02-04 | Dominic Smethurst | Chief Medical Officer | A | +27,200 | — |
| 2025-02-04 | Sean F. Moran | Chief Financial Officer | A | +27,500 | — |
| 2024-09-24 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | Buy | +350,000 | +$7.00M |
| 2024-08-20 | Winston Kung | Director | A | +5,566 | — |
| 2024-06-18 | Sean F. Moran | Chief Financial Officer | MIXED | — | −$630.02K |
| 2024-06-18 | Yuval Cohen | Chief Executive Officer | MIXED | −7,179 | −$1.99M |
| 2024-06-14 | Alan F Holmer | Director | M | +1,667 | +$50.01K |
| 2024-06-03 | Avery W Catlin | Director | A | +2,783 | — |
| 2024-06-03 | Anne Altmeyer | Director | A | +2,783 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cormorant Asset Management, LP | 10%+ Owner | 2,344,971 | $8.25M |
| Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | 1,919,971 | $6.76M |
| Yuval Cohen | Chief Executive Officer | 157,316 | $553.75K |
| Dominic Smethurst | Chief Medical Officer | 89,790 | $316.06K |
| Sean F. Moran | Chief Financial Officer | 84,694 | $298.12K |
| Nishant C Saxena | Chief Business Officer | 77,900 | $274.21K |
| Leonardo Viana Nicacio | Chief Medical Officer | 58,333 | $205.33K |
| Ian Hodgson | Chief Operating Officer | 51,080 | $179.80K |
| Winston Kung | Director | 12,140 | $42.73K |
| Rachelle Suzanne Jacques | Director | 11,383 | $40.07K |
| Alan F Holmer | Director | 10,629 | $37.41K |
| Yong Ben | Director | 9,383 | $33.03K |
| Anne Altmeyer | Director | 7,579 | $26.68K |
| Brent Pfeiffenberger | Director | 7,500 | $26.40K |
| John Kenneth Jenkins | Director | 3,833 | $13.49K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRBP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.